In a bid to contain prescription drug prices, a pair of U.S. senators is re-introducing a bill to have the Government Accountability Office probe the role of pharmacy benefit managers in the opaque pharmaceutical supply chain.
The legislation is only the latest effort to focus on these controversial middlemen, which create formularies, or lists of medicines that are covered by insurance. In the process, pharmacy benefit managers collect rebates from drug makers, a controversial tactic because the deals are blamed for rising drug prices, but the amounts are kept confidential.
About the Author Reprints
